Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

DMK Pharmaceuticals Regains Full Rights From U.S. WorldMeds For SYMJEPI And Provides Corporate Update

Author: Benzinga Newsdesk | November 28, 2023 09:06am

The Company is now actively seeking out-license opportunities for SYMJEPI® in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.

Posted In: DMK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist